NSRI launches study of emergent technologies to help protect warfighters from gamma radiation
OMAHA, Neb., Dec. 3, 2025 /PRNewswire/ — The National Strategic Research Institute (NSRI) at the University of Nebraska has launched a study for the Office... Read more.
Neon One Customers Raise a Record $25.6 Million from 50,000 Donors on GivingTuesday, Proving Power of Relationship-Based Fundraising
CHICAGO, Dec. 3, 2025 /PRNewswire/ — Neon One, the leading nonprofit relationship management platform, announced that its nonprofit customers raised a record-breaking... Read more.
Minton Innovation Solutions Announces Low-Cost Business Growth Program utilizing OTAs and CSOs
Any commercial company can leverage the new program by reaching out to MISÂ WOODBRIDGE, Va., Dec. 3, 2025 /PRNewswire/ —Â Minton Innovation Solutions, located... Read more.
roommaster Earns 2025 Certificate Of Excellence From HotelTechReport
CLEARWATER, Fla., Dec. 3, 2025 /PRNewswire/ — roommaster, the modern hotel management solution for independent properties, has been awarded the 2025 Certificate... Read more.
Kibu CEO Daniel Caridi Named to Forbes 30 Under 30 List for Social Impact
STAMFORD, Conn., Dec. 3, 2025 /PRNewswire/ — Kibu, a person-centered platform for disability service providers, announced today that Co-Founder and CEO Daniel... Read more.
Whittier College Receives Historic Second Gift From Philanthropist MacKenzie Scott
Gift Marks a Resounding Vote of Confidence in Whittier College’s Future WHITTIER, Calif., Dec. 3, 2025 /PRNewswire/ —Â Whittier College is thrilled to... Read more.
Korea’s Startups Poised for a Landmark Season as COMEUP 2025 and CES 2026 Draw Near
SEOUL, South Korea, Dec. 3, 2025 /PRNewswire/ — Korea is preparing for a defining season in global innovation, as Seoul readies for COMEUP 2025—hosted by... Read more.
U.S. FDA approves expanded indication for Lilly’s Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent... Read more.
Announcing S4GEO – The Society for Geopolitics | Bringing together providers and consumers of geopolitical strategy and intelligence
NEW YORK, Dec. 3, 2025 /PRNewswire/ — The field of geopolitics has become a daily concern for business leaders. From the emergence of groups like Strategic... Read more.
A Sparkling Fit: Evive Brands Strengthens Platform With Shine Acquisition
JENISON, Mich., Dec. 3, 2025 /PRNewswire/ — Evive Brands, a leading community of service-focused franchise companies, today announced it has acquired Shine,... Read more.